Plasma free amino acid profiling of esophageal cancer using high-performance liquid chromatography spectroscopy

Ma, Hong; Hasim, Ayshamgul; Mamtimin, Batur; Kong, Bin; Zhang, Haiping; Sheyhidin, Ilyar

doi:10.3748/wjg.v20.i26.8653

Cited by 44 publications

(40 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These compounds are easily identified on both NMR and MS platforms, and several studies employed a targeted amino acid methodology (47,55,63,64). However, amino acids were not specific as clinical cancer biomarkers.…”

Section: Discussionmentioning

confidence: 99%

Diagnostic Metabolomic Blood Tests for Endoluminal Gastrointestinal Cancer—A Systematic Review and Assessment of Quality

Antonowicz

Kumar

Wiggins

et al. 2016

Cancer Epidemiology, Biomarkers &Amp; Prevention

View full text Add to dashboard Cite

Advances in analytics have resulted in metabolomic blood tests being developed for the detection of cancer. This systematic review aims to assess the diagnostic accuracy of blood-based metabolomic biomarkers for endoluminal gastrointestinal (GI) cancer. Using endoscopic diagnosis as a reference standard, methodologic and reporting quality was assessed using validated tools, in addition to pathway-based informatics to biologically contextualize discriminant features. Twenty-nine studies (15 colorectal, 9 esophageal, 3 gastric, and 2 mixed) with data from 10,835 participants were included. All reported significant differences in hematologic metabolites. In pooled analysis, 246 metabolites were found to be significantly different after multiplicity correction. Incremental metabolic flux with disease progression was frequently reported. Two promising candidates have been validated in independent populations (both colorectal biomarkers), and one has been approved for clinical use. Networks analysis suggested modulation of elements of up to half of Edinburgh Human Metabolic Network subdivisions, and that the poor clinical applicability of commonly modulated metabolites could be due to extensive molecular interconnectivity. Methodologic and reporting quality was assessed as moderate-to-poor. Serum metabolomics holds promise for GI cancer diagnostics; however, future efforts must adhere to consensus standardization initiatives, utilize high-resolution discovery analytics, and compare candidate biomarkers with peer nonendoscopic alternatives.Cancer Epidemiol Biomarkers Prev; 25(1); 6-15. Ó2015 AACR.

show abstract

Section: Discussionmentioning

confidence: 99%

Diagnostic Metabolomic Blood Tests for Endoluminal Gastrointestinal Cancer—A Systematic Review and Assessment of Quality

Antonowicz

Kumar

Wiggins

et al. 2016

Cancer Epidemiology, Biomarkers &Amp; Prevention

View full text Add to dashboard Cite

show abstract

“…Metabolomics, the global semi-quantitative assessment of endogenous small molecule metabolites within a biological system, has been successfully utilized in cancer biomarker discovery (Spratlin et al 2009;Zhang et al 2013, b;Ke et al 2015). Up to now, a few ESCC metabolomics studies has been reported using specimen of serum (Djukovic et al 2010;Zhang et al 2011;Ikeda et al 2012;Zhang et al 2012aZhang et al , b, 2013Jin et al 2014;Mir et al 2015), plasma (Hasim et al 2012;Liu et al 2013;Xu et al 2013;Ma et al 2014), urine (Davis et al 2012;Hasim et al 2012), tissue (Wu et al 2009;Yakoub et al 2010;Wang et al 2013;Yang et al 2013;Lynam-Lennon et al 2014) or gastric content (Kumar et al 2012), and conducted on mass spectrometry (MS) and nuclear magnetic resonance (NMR) platforms. These studies revealed significantly perturbed metabolic expression in ESCC patients compared with healthy controls.…”

Section: Introductionmentioning

confidence: 95%

Serum metabolomics for early diagnosis of esophageal squamous cell carcinoma by UHPLC-QTOF/MS

et al. 2016

View full text Add to dashboard Cite

Introduction Previous metabolomics studies have revealed perturbed metabolic signatures in esophageal squamous cell carcinoma (ESCC) patients, however, most of these studies included mainly late-staged ESCC patients due to the difficulties of collecting the early-staged samples from asymptotic ESCC subjects. Objectives This study aims to explore the early-staged ESCC metabolic signatures and potential of serum metabolomics to diagnose ESCC at early stages. Methods Serum samples of 97 ESCC patients (stage 0, 39 cases; stage I, 17 cases; stage II, 11 cases, stage III, 30 cases) and 105 healthy controls (HC) were enrolled and randomly separated into training data (77 ESCCs, 84 HCs) and validation data (20 ESCCs, 21 HCs). Untargeted metabolomics was performed to identify ESCC-related metabolic signatures. ResultsThe global metabolomics profiles could clearly distinguish ESCC from HC in training data. 16 ascertained metabolites were found to be disturbed in the metabolic pathways characterized by dysregulated fatty acid biosynthesis, glycerophospholipid metabolism, choline metabolism in cancer and linoleic acid metabolism. The AUC value in validation data was 0.895, with sensitivity 85.0 % and specificity 90.5 %. Good diagnostic performances were also achieved for early stage ESCC, with the values of area under the curve (AUC) 0.881 for the ESCC patients in both stage 0 and I-II. In addition, six metabolites were found to discriminate ESCC stages. Among them, three biomarkers, dodecanoic acid, LysoPA(18:1), and LysoPC(14:0), exhibited clear trend for ESCC progression. Conclusion These findings suggest serum metabolomics, performed in a minimally noninvasive and convenient manner, may possess great potential for early diagnosis of ESCC patients.

show abstract

“…The new methodology of development of minicomponents infusion solutions offered by us on the basis of amino acids intended for correction of the metabolic imbalance arising at various localization and stages of the malignant growth is based on results of research of regularities of formation of amino-acid fund in biological liquids and tissues. The ratios of the individual components and their quantity in such mixtures should comply with their physiological (endogenous) concentrations in the normal blood plasma and tissues [17][18][19][20][21].…”

Section: Resultsmentioning

confidence: 99%

The Amino Acid Pool in Oncology: Plastic Substrates, Specific Regulators of Metabolism and Markers

Karavay¹,

Karavay²,

Nefyodov³

2017

J Pat Care

View full text Add to dashboard Cite

On the basis of experimental data we suggest that discovered differences in certain amino acids concentrations in blood plasma, red blood cells and tumors are criteria in early diagnostic of primary cancerous growth as well as, in estimation of the effectiveness of specific cancer treatment. In clinical studies (1,495 patients with cancer of mammary gland, lungs, prostate, ovaries, bladder or digestive tract) biological fluids and tumors of cancer patients significant changes of physiological concentrations of amino acids real or indirectly regulate processes of the antitumor response, oncogenesis, immunogenesis and apoptosis were shown. Our strategy of application of amino acids as medicinal preparations includes a directional effect on the functional and metabolic relationships which change in specific pathology through the effect on the regulatory mechanisms of intermediate metabolic reactions, limiting stages of metabolic flows, utilization of energy substrates and transport systems restricting the processes of amino acids pool formation. The creation methodology of pathogenetic compositions of amino acids and their derivatives on the basis of their physiological concentration for practical application in oncology of their regulatory effects was discussed.that practically ignored their regulatory effects on metabolic processes and key metabolic reactions.To understand the metabolic processes and vital functions of the regulatory effect of amino acids, this manifests itself under natural or near concentrations of these compounds in body fluids and tissues. It is obvious that the effective use of L-amino acids or their derivatives for metabolic correction and directional changes in metabolism in pathological or extreme conditions limited accumulation of information about theme mechanisms of regulatory effects of the compounds tested at concentrations comparable to their physiological (endogenous) level [1][2][3][4][5][6][7][8][9][10]. Materials and Methods Our development methodology is based on• The study of physiological concentrations of free amino acids, their derivatives, precursors and metabolites, as well as, biochemical marker parameters in healthy donors and patients with various pathologies.• Creating a unified database for the studied parameters, construction of empirical mathematical model consisting of pathogenic markers specific pathology and amino acid profiles.• Specialized development of new formulations of the compositions of infusion solutions of amino acids and their Journal of Patient CareJo u r n al of Pati en t C a re

show abstract

Plasma free amino acid profiling of esophageal cancer using high-performance liquid chromatography spectroscopy

Abstract: HPLC-based plasma profiling analysis was shown to be an effective approach to differentiate between ESCC patients and controls. PFAA profiles may have potential value for screening or diagnosing ESCC.

Cited by 44 publications

References 24 publications

Diagnostic Metabolomic Blood Tests for Endoluminal Gastrointestinal Cancer—A Systematic Review and Assessment of Quality

Diagnostic Metabolomic Blood Tests for Endoluminal Gastrointestinal Cancer—A Systematic Review and Assessment of Quality

Serum metabolomics for early diagnosis of esophageal squamous cell carcinoma by UHPLC-QTOF/MS

The Amino Acid Pool in Oncology: Plastic Substrates, Specific Regulators of Metabolism and Markers

Contact Info

Product

Resources

About